Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Total Non-Current Liabilities (2019 - 2026)

ADC Therapeutics has reported Total Non-Current Liabilities over the past 8 years, most recently at $489.4 million for Q1 2026.

  • Quarterly results put Total Non-Current Liabilities at $489.4 million for Q1 2026, down 3.35% from a year ago — trailing twelve months through Mar 2026 was $489.4 million (down 3.35% YoY), and the annual figure for FY2025 was $509.0 million, down 2.53%.
  • Total Non-Current Liabilities reached $489.4 million in Q1 2026 per ADCT's latest filing, down from $509.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $522.2 million in Q4 2024 and bottomed at $331.1 million in Q4 2022.
  • Median Total Non-Current Liabilities over the past 5 years was $494.2 million (2023), compared with a mean of $449.2 million.
  • Peak annual rise in Total Non-Current Liabilities hit 184.82% in 2022, while the deepest fall reached 13.28% in 2022.
  • Over 5 years, Total Non-Current Liabilities stood at $331.1 million in 2022, then skyrocketed by 49.24% to $494.2 million in 2023, then grew by 5.67% to $522.2 million in 2024, then decreased by 2.53% to $509.0 million in 2025, then decreased by 3.85% to $489.4 million in 2026.
  • Business Quant data shows Total Non-Current Liabilities for ADCT at $489.4 million in Q1 2026, $509.0 million in Q4 2025, and $518.5 million in Q3 2025.